Yanan Zhu
Stock Analyst at Wells Fargo
(1.91)
# 3,160
Out of 5,072 analysts
84
Total ratings
32.86%
Success rate
-5.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $80 → $60 | $27.96 | +114.59% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $8.55 | +40.35% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $19.35 | +132.56% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $29.97 | +140.24% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $6.80 | +194.12% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.39 | +67.36% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $40.44 | +11.28% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $80.93 | +1.32% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.67 | +618.56% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $4.59 | +74.29% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.06 | +135.85% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.39 | +259.71% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.48 | +464.52% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $71.55 | +4.82% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $24.69 | +183.52% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.97 | +151.89% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $29.19 | +37.06% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $53.57 | +21.34% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.71 | +289.11% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.42 | +863.62% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.45 | +12,943.48% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $917.93 | -64.49% | 1 | Feb 2, 2021 |
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $27.96
Upside: +114.59%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $8.55
Upside: +40.35%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.35
Upside: +132.56%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $29.97
Upside: +140.24%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $6.80
Upside: +194.12%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.39
Upside: +67.36%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $40.44
Upside: +11.28%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $80.93
Upside: +1.32%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.67
Upside: +618.56%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $4.59
Upside: +74.29%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.06
Upside: +135.85%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.39
Upside: +259.71%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.48
Upside: +464.52%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $71.55
Upside: +4.82%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $24.69
Upside: +183.52%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.97
Upside: +151.89%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $29.19
Upside: +37.06%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $53.57
Upside: +21.34%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $7.71
Upside: +289.11%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.42
Upside: +863.62%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.45
Upside: +12,943.48%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $917.93
Upside: -64.49%